Research programme: antibody therapeutics - Biotecnol

Drug Profile

Research programme: antibody therapeutics - Biotecnol

Alternative Names: CAB051; IR051; IR052; Tb 434; Tb 535

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotecnol SA
  • Developer Biotecnol Inc.
  • Class Antibodies
  • Mechanism of Action CD3 antigen inhibitors; ERBB 2 receptor antagonists; Signal transducing adaptor protein inhibitors; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Mesothelioma
  • No development reported Breast cancer; Gastric cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Portugal (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for research development in Breast-cancer in Portugal (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for research development in Gastric-cancer in Portugal (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top